Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

Science

Volumn 281, Issue 5381, 1998, Pages 1349-1352

  Moghaddam, Bita ^a   Adams, Barbara W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; EGLUMETAD; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STEREOTYPY; SUBSTANCE ABUSE; WORKING MEMORY;

ANIMALIA;

EID: 0032575715     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.281.5381.1349     Document Type: Article

References (46)

1. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
2. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
3. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
4. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
5. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
6. J. S. Kim, H. H. Kornhuber, W. Schmid-Burgk, B. Holzmuller, Neurosci. Lett. 20, 379 (1980); J. F. W. Deakin et al., J. Neurochem. 52, 1781 (1989); D. Javitt and S. Zukin, Am. J. Psychiatry 148, 1301 (1991); B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), pp. 1205-1214; J. Coyle, Harvard Rev. Psychiatry 3, 241 (1996); C. A. Tamminga, Crit. Rev. Neurobiol. 12, 21 (1998).
7. J. F. W. Deakin, P. Slater, M. D. C. Simpson, M. C. Royston, Br. J. Psychiatry 157, 459 (1990); F. M. Benes et al., Cereb. Cortex 2, 503 (1992); J. W. Olney and N. B. Farber, Arch. Gen. Psychiatry 52, 998 (1995).
8. J. F. W. Deakin, P. Slater, M. D. C. Simpson, M. C. Royston, Br. J. Psychiatry 157, 459 (1990); F. M. Benes et al., Cereb. Cortex 2, 503 (1992); J. W. Olney and N. B. Farber, Arch. Gen. Psychiatry 52, 998 (1995).
9. J. F. W. Deakin, P. Slater, M. D. C. Simpson, M. C. Royston, Br. J. Psychiatry 157, 459 (1990); F. M. Benes et al., Cereb. Cortex 2, 503 (1992); J. W. Olney and N. B. Farber, Arch. Gen. Psychiatry 52, 998 (1995).
10. W. J. Schmidt, J. Neural Transm. Suppl. 43, 63 (1994). S. D. Iversen, Behav. Pharmacol. 6, 478 (1995); A. Carlsson, A. Svensson, M. L. Carlsson, Future Strategies in the Discovery of New Antipsychotic Agents: Focus on Dopamine-Glutamate Interactions (Karger, Basel, Switzerland, 1993), vol. 4, pp. 118-129.
11. W. J. Schmidt, J. Neural Transm. Suppl. 43, 63 (1994). S. D. Iversen, Behav. Pharmacol. 6, 478 (1995); A. Carlsson, A. Svensson, M. L. Carlsson, Future Strategies in the Discovery of New Antipsychotic Agents: Focus on Dopamine-Glutamate Interactions (Karger, Basel, Switzerland, 1993), vol. 4, pp. 118-129.
12. W. J. Schmidt, J. Neural Transm. Suppl. 43, 63 (1994). S. D. Iversen, Behav. Pharmacol. 6, 478 (1995); A. Carlsson, A. Svensson, M. L. Carlsson, Future Strategies in the Discovery of New Antipsychotic Agents: Focus on Dopamine-Glutamate Interactions (Karger, Basel, Switzerland, 1993), vol. 4, pp. 118-129.
13. E. D. Luby, B. D. Cohen, G. Rosenbaum, J. S. Gottlieb, R. Kelley, Am. Med. Assoc. Arch. Neurol. Psychiatry 81, 363 (1959); J. H. Krystal et al., Arch. Gen. Psychiatry 51, 199 (1994); A. K. Malhotra et al., Neuropsychopharmacology 14, 301 (1996).
14. E. D. Luby, B. D. Cohen, G. Rosenbaum, J. S. Gottlieb, R. Kelley, Am. Med. Assoc. Arch. Neurol. Psychiatry 81, 363 (1959); J. H. Krystal et al., Arch. Gen. Psychiatry 51, 199 (1994); A. K. Malhotra et al., Neuropsychopharmacology 14, 301 (1996).
15. E. D. Luby, B. D. Cohen, G. Rosenbaum, J. S. Gottlieb, R. Kelley, Am. Med. Assoc. Arch. Neurol. Psychiatry 81, 363 (1959); J. H. Krystal et al., Arch. Gen. Psychiatry 51, 199 (1994); A. K. Malhotra et al., Neuropsychopharmacology 14, 301 (1996).
16. A. C. Lahti, B. Koffel, D. LaPorte, C. A. Tamminga, Neuropsychopharmacology 13, 9 (1995); A. K. Malhotra et al., ibid. 17, 141 (1997).
17. A. C. Lahti, B. Koffel, D. LaPorte, C. A. Tamminga, Neuropsychopharmacology 13, 9 (1995); A. K. Malhotra et al., ibid. 17, 141 (1997).
18. D. D. Schoepp and P. J. Conn, Trends Pharmacol. Sci. 14, 13 (1993); S. Nakanishi and M. Masu, Annu. Rev. Biophys. Biomol. Struct. 23, 319 (1994); P. J. Conn and J.-P. Pin, Annu. Rev. Pharmacol. Toxicol. 37, 205 (1997).
19. D. D. Schoepp and P. J. Conn, Trends Pharmacol. Sci. 14, 13 (1993); S. Nakanishi and M. Masu, Annu. Rev. Biophys. Biomol. Struct. 23, 319 (1994); P. J. Conn and J.-P. Pin, Annu. Rev. Pharmacol. Toxicol. 37, 205 (1997).
20. D. D. Schoepp and P. J. Conn, Trends Pharmacol. Sci. 14, 13 (1993); S. Nakanishi and M. Masu, Annu. Rev. Biophys. Biomol. Struct. 23, 319 (1994); P. J. Conn and J.-P. Pin, Annu. Rev. Pharmacol. Toxicol. 37, 205 (1997).
21. R. S. Petralia, Y.-X. Wang, A. S. Niedzielski, R. J. Wenthold, Neuroscience 71, 949 (1996).
22. S. J. East, M. P. Hill, J. M. Brotchie, Eur. J. Pharmacol. 277, 117 (1995); P. Foley, Br. J. Pharmacol. 116, 111 (1995).
23. S. J. East, M. P. Hill, J. M. Brotchie, Eur. J. Pharmacol. 277, 117 (1995); P. Foley, Br. J. Pharmacol. 116, 111 (1995).
24. G. Battaglia, J. A. Monn, D. D. Schoepp, Neurosci. Lett. 229, 161 (1997).
25. D. M. Lovinger and B. A. McCool, J. Neurophysiol. 73, 1076 (1995); M. Yoshino, S. Sawada, C. Yamamoto, H. Kamiya, Neurosci. Lett. 207, 70 (1996).
26. D. M. Lovinger and B. A. McCool, J. Neurophysiol. 73, 1076 (1995); M. Yoshino, S. Sawada, C. Yamamoto, H. Kamiya, Neurosci. Lett. 207, 70 (1996).
27. B. Moghaddam, B. Adams, A. Verma, D. Daly, J. Neurosci. 17, 2921 (1997).
28. B. Adams and B. Moghaddam, ibid. 18, 5545 (1998).
29. D. L. Willins, S. Narayanan, L. J. Wallace, N. J. Uretsky, Pharmacol. Biochem. Behav. 46, 881 (1993); M. Bubser, T. Tzschentke, W. Hauber, J. Neural Transm. Gen. Sect. 101, 115 (1995).
30. D. L. Willins, S. Narayanan, L. J. Wallace, N. J. Uretsky, Pharmacol. Biochem. Behav. 46, 881 (1993); M. Bubser, T. Tzschentke, W. Hauber, J. Neural Transm. Gen. Sect. 101, 115 (1995).
31. A. Anand et al., Soc. Neurosci. Abstr. 23, 686.3 (1997).
32. D. D. Schoepp et al., Neuropharmacology 36, 1 (1997); D. R. Helton, J. P. Tizzano, J. A. Monn, D. D. Schoepp, M. Jeanne, J. Pharmacol. Exp. Ther. 284, 651 (1998).
33. D. D. Schoepp et al., Neuropharmacology 36, 1 (1997); D. R. Helton, J. P. Tizzano, J. A. Monn, D. D. Schoepp, M. Jeanne, J. Pharmacol. Exp. Ther. 284, 651 (1998).
34. Animals were treated with vehicle or LY354740 before they were injected with a moderate dose of PCP (1 and 5 mg/kg ip injection). Measurements were made of (i) in vivo extracellular glutamate concentrations in the prefrontal cortex and nucleus accumbens, (ii) in vivo extracellular dopamine concentrations in the prefrontal cortex and nucleus accumbens, (iii) locomotor activity, (iv) stereotypy, and (v) performance in a T-maze discrete-trial delayed alternation task, a rodent working memory paradigm. Animal use procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, 1996) and were approved by the Yale University Animal Care and Use Committee. Microdialysis and behavioral measures were performed in awake, freely moving rats (male Sprague-Dawley, 275 to 325 g) as described in (12). Microdialysis and locomotor data were analyzed by repeated measures of analysis of variance (ANOVA). The delayed alternation data were compared by multifactorial ANOVA followed by Tukey post hoc analysis. Significance was set at P < 0.05.
35. S. O. Ogren and M. Goldstein, Neuropsychopharmacology 11, 167 (1994).
36. M. Carlsson and A. Carlsson, J. Neural Transm. 75, 221 (1989); J. P. Druhan, H. Rajabi, J. Stewart, Synapse 24, 135 (1996).
37. M. Carlsson and A. Carlsson, J. Neural Transm. 75, 221 (1989); J. P. Druhan, H. Rajabi, J. Stewart, Synapse 24, 135 (1996).
38. T. W. Robbins, Schizophr. Bull. 16, 391 (1990).
39. P. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), pp. 1-23.
40. E. Bleuler, Dementia Praecox or the Group of Schizophrenias (International Universities Press, New York, 1950); N. Lyon, B. Mejsholm, M. Lyon, J. Psychiatr. Res. 20, 137 (1986).
41. E. Bleuler, Dementia Praecox or the Group of Schizophrenias (International Universities Press, New York, 1950); N. Lyon, B. Mejsholm, M. Lyon, J. Psychiatr. Res. 20, 137 (1986).
42. R. S. Burns and S. E. Lerner, Clin. Toxicol. 9, 477 (1976).
43. C. Tsai et al., Arch. Cen. Psychiatry 52, 829 (1995).
44. B. Wroblewska et al., J. Neurochem. 69, 174 (1997).
45. B. Moghaddam and B. W. Adams, data not shown.
46. We thank D. Schoepp for helpful discussions and for assisting us in obtaining LY354740, J. Aultman for technical assistance, and the National Institute of Mental Health for supporting this research.